Brief: Mirum Pharmaceuticals Q4 Operating Expenses USD 153.499 Million
25/02/2026 21:01
Feb 25 (Reuters) - Mirum Pharmaceuticals Q4 product sales USD 148.932 million. Q4 net income USD -5.73 million Q4 operating income USD -4.567 million
Recent news on Mirum Pharmaceuticals
See all newsMirum Pharmaceuticals Q3 net product sales surge, outlook raised
Brief: Mirum Pharmaceuticals Announces Positive Results From Cohort 2 Of The Pivotal Progress Study Of Atebrioz™ (Zilurgisertib) In Pediatric Patients Aged 6 To <12 Years With Fibrodysplasia Ossificans Progressiva
Mirum climbs on positive late-stage trial results for liver disease drug
US STOCKS ON THE MOVE-Mirum Pharmaceuticals, Meta, Boeing
U.S. STOCKS ON THE MOVE-Royal Caribbean Cruises, SpaceX